• Karyopharm Therapeutics secured creditor support under a restructuring support agreement for its proposed prepackaged Chapter 11 plan.
• Supporting holders represent 100% of 1L Term Loan Claims, 1.5L 2028 Notes Claims and 2L 2029 Notes Claims.
• Holders of 100% of RIFA Claims also support the plan, which requires bankruptcy court confirmation.
• Votes are due November 30, 2026, at 4 p.m. Central Time; allowed general unsecured claims would remain unimpaired.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-444164), on November 03, 2026, and is solely responsible for the information contained therein.